Under the terms of the agreement, Alchemab will collaborate with Lilly to discover, develop and commercialise up to five novel therapeutics. Alchemab will receive an undisclosed upfront payment ...

Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...

Alchemab’s chief executive officer, Jane Osbourn, commented: “As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly’s deep expertise in ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The collaboration agreement centres around Alchemab’s antibody discovery platform, ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company . Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses ...

Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...

Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...